Seres Therapeutics Inc - ESG Rating & Company Profile powered by AI
The ESG rating includes 17 United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Industry, Innovation & Infrastructure' and 'Partnerships for the Goals'. Detailed ESG assessment of Seres Therapeutics Inc are reached by signing in. The report of Seres Therapeutics Inc is assembled by All Street Sevva using cutting edge NLP.
Seres Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.1; made up of an environmental score of 1.6, social score of 3.2 and governance score of 6.7.
4.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Novartis AG | 9.2 | High |
2 | Daiichi Sankyo Co Ltd | 8.9 | High |
1376 | Vericel Corp | 4.2 | High |
1376 | vTv Therapeutics Inc | 4.2 | High |
1412 | Seres Therapeutics Inc | 4.1 | High |
1412 | Abivax SA | 4.1 | High |
1412 | Aeglea Bio Therapeutics Inc | 4.1 | High |
... | ... | ... | |
2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
2749 | Zyden Gentec Ltd | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does Seres Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Seres Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Seres Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Seres Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Seres Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Seres Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Seres Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Seres Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Seres Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Seres Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Seres Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Seres Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Seres Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Seres Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Seres Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Seres Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Seres Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Seres Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.